Institutional Ownership and Concentration of Capital in Pharmaceutical Companies: Evidence from Iran

سال انتشار: 1402
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 183

فایل این مقاله در 13 صفحه با فرمت PDF قابل دریافت می باشد

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این مقاله:

شناسه ملی سند علمی:

JR_EBHPME-7-4_006

تاریخ نمایه سازی: 12 خرداد 1403

چکیده مقاله:

Background: Institutional owners influence the direction of policy and the performance of owned companies. This research was motivated by the presence of pharmaceutical companies in the Tehran Stock Exchange and the uncertainty surrounding the extent and influence of institutional owners on the policy direction and performance of the companies. Methods: This was a descriptive-analytical and cross-sectional study. The descriptive phase of the study involved measuring sales figures, market value, and market share of pharmaceutical companies listed on the stock exchange. In the analytical phase, the network of shareholders' relationships was analyzed with Gephi version ۰.۱ and Microsoft Excel version ۲۰۱۶, followed by the calculation of the capital concentration index and market share. Results: Estimates indicated that approximately ۴۵% of the pharmaceutical companies in Iran were publicly traded in stock exchange. In ۲۰۲۰, the total value of these companies in the Iranian capital market reached ۹.۷۹ billion USD. Out of this amount, ۴۵% (equivalent to ۴.۴ billion USD) was offered in Tehran Stock Exchange. The concentration of final shareholders, with a Herfindahl–Hirschman index(HHI) index of ۰.۰۳۶, signified a monopolistic competition market. On the other hand, the pharmaceutical capital market could be classified as an oligopoly market (with a CR۴ value of ۵۸.۳) when analyzing only the direct shareholders at level ۲. Additionally, the six main holding companies at this level collectively possess ۶۷% of the pharmaceutical capital market. Conclusion: Based on the results, the importance of institutional owners, such as the Social Security Organization (SSO), in the decision-making process regarding the Iranian pharmaceutical market can be acknowledged. The decisions about integration and supply chains which aimed at improving the productivity of the pharmaceutical market, need to be thoroughly examined by the institutions mentioned in this research.

نویسندگان

Rouhollah Yaghoubi

Department of Health Management, Policy and Economics, School of public Health, Tehran University of Medical Sciences, Tehran, Iran

Sara Emamgholipour

Department of Health Management, Policy and Economics, School of public Health, Tehran University of Medical Sciences, Tehran, Iran

Amin Mohammadi

Department of Health Management, Policy and Economics, School of public Health, Tehran University of Medical Sciences, Tehran, Iran

Bashir Azimi Nayebi

School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran

Abdoreza Mousavi

Department of Health Management, Policy and Economics, School of public Health, Tehran University of Medical Sciences, Tehran, Iran

Fakhraddini Dastari

School of Management and Medical Informatics, Tabriz University of Medical Sciences, Tabriz, Iran

مراجع و منابع این مقاله:

لیست زیر مراجع و منابع استفاده شده در این مقاله را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود مقاله لینک شده اند :
  • Heidari H, Mohammadzadeh Y, Refah-Kahriz A. An investigation of the ...
  • Yusefzadeh H, Rezapour A, Lotfi F, Azar FE, Nabilo B, ...
  • Zarei G, Zarei T, Farajzadeh S. Anti-marketing of Drug Abuse ...
  • Masoumi M, Azar FEF, RezaPour A, Mehrara M. Economic and ...
  • Mohseni M, Gorji HA, Ahadinezhad B, Khosravizadeh O, Keykaleh MS, ...
  • Davari M, Walley T, Haycox A. Pharmaceutical policy and market ...
  • Mohajerani A, Mashayekhi A, Talebian M, Corporate governance in Iran: ...
  • Brammer S, Millington A, Rayton B. The contribution of corporate ...
  • Saboohi N, Mohamadzadeh A. Investigating the relationship between social performance, ...
  • Osta S. Investigating the relationship between Ownership Structure and Earning ...
  • Velury U, Jenkins DS. Institutional ownership and the quality of ...
  • Kazemi H, Saadatinezhad Z. Investigating the relationship between ownership structure ...
  • Lehmann E, Weigand J. Does the governed corporation perform better? ...
  • Rezaei F, Mohammadizadeh M. The Role of Corporate Governance and ...
  • Jiang L, Kim J-B. Cross-corporate ownership, information asymmetry and the ...
  • Farooq O. Effect of ownership concentration on capital structure: evidence ...
  • Iranian Ministry of Health and Medical Education. Pharmaceutical Statistics ۲۰۱۷. ...
  • Tehran Securities Exchange Technology Management Co. Tehran Securities Exchange. Available ...
  • Delory E, Pearlman J. Challenges and Innovations in Ocean In ...
  • Rezaei F, Haqiq H. Industry Concentration and Manufacturing Industries Stock ...
  • Hannan TH. Market Share Inequality, the Number of Competitors, and ...
  • Bank Pricing. Review of Industrial Organization ...
  • ۱۹۹۷; ۱۲(۱): ۲۳-۳۵. https://doi.org/۱۰.۱۰۲۳/ A: ۱۰۰۷۷۴۴۱۱۹۳۷ ...
  • Demsetz H. Industry structure, market rivalry, and public policy. The ...
  • Rhoades SA. The herfindahl-hirschman index. Fed Res Bull. ۱۹۹۳;۷۹:۱۸۸ ...
  • Brezina I, Pekár J, Čičková Z, Reiff M. Herfindahl–Hirschman index ...
  • The Central Bank of Iran. Foreign Exchange Rates. Available from ...
  • Masoumi M, Ebadi Fard Azar F, RezaPour A, Mehrara M. ...
  • The Central Bank of Iran. Foreign Exchange Rates. Available from ...
  • Yusefzadeh H, Hadian M, Abolghasem Gorji H, Ghaderi H. Assessing ...
  • Richman B, Mitchell W, Vidal E, Schulman K. Pharmaceutical M&A ...
  • Gautam A, Pan X. The changing model of big pharma: ...
  • Poor Partovi MT, Danesh Jafari D, Jalalabadi A. Comparative Study ...
  • نمایش کامل مراجع